{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:25:09Z","timestamp":1785835509045,"version":"3.56.0"},"reference-count":22,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the effect of erenumab on patient-reported, functional outcomes in patients with episodic migraine (EM) in whom 2\u20134 preventives were not useful from the Phase 3b LIBERTY study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>As previously reported, 246 patients with EM with 2\u20134 prior failed preventives were randomised 1:1 to subcutaneous erenumab 140\u2009mg or placebo every 4\u2009weeks for 12\u2009weeks. This analysis evaluated Migraine Physical Function Impact Diary (MPFID), Headache Impact Test (HIT-6) and Work Productivity and Activity Impairment (WPAI) scores at Week 12. P values were nominal without multiplicity adjustment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Erenumab significantly improved MPFID-Physical Impairment (PI) and Everyday Activities (EA) scores versus placebo (treatment difference (TD) (95%\u2009CI) MPFID-PI: \u22123.5 (\u22125.7 to \u20131.2) (p=0.003); MPFID-EA: \u22123.9 (\u22126.1 to \u20131.7)) (p&lt;0.001) at 12 weeks. Patients on erenumab were more likely to have a \u22655-point reduction in MPFID score (OR vs placebo (95%\u2009CI) MPFID-EA: 2.1 (1.2 to 3.6); MPFID-PI: 2.5 (1.4 to 4.5)). A similar trend was observed for HIT-6 (TD: \u22123.0; p&lt;0.001); significantly higher proportions of patients on erenumab reported a \u22655-point reduction (OR (95%\u2009CI): 2.4 (1.4 to 4.1)). In three out of four WPAI domains, erenumab showed improvement versus placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>At 12 weeks, erenumab was efficacious on functional outcomes in patients with EM in whom 2\u20134 preventives were not useful.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration details<\/jats:title><jats:p>ClinicalTrials.gov identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03096834\">NCT03096834<\/jats:ext-link>.<\/jats:p><\/jats:sec>","DOI":"10.1136\/jnnp-2020-324396","type":"journal-article","created":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T21:25:04Z","timestamp":1609881904000},"page":"466-472","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Effect of erenumab on functional outcomes in patients with episodic migraine in whom 2\u20134 preventives were not useful: results from the LIBERTY study"],"prefix":"10.1136","volume":"92","clinical-trial-number":[{"clinical-trial-number":"nct03096834","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03096834","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michel","family":"Lanteri-Minet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3260-5904","authenticated-orcid":false,"given":"Peter J","family":"Goadsby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Reuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihua","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy","family":"Hours-Zesiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel D","family":"Ferrari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2276-4701","authenticated-orcid":false,"given":"Jan","family":"Klatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"2022011608400584000_92.5.466.1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.115.227793"},{"key":"2022011608400584000_92.5.466.2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418759786"},{"key":"2022011608400584000_92.5.466.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705848"},{"key":"2022011608400584000_92.5.466.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30083-2"},{"key":"2022011608400584000_92.5.466.5","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1177\/0333102418788347","article-title":"Efficacy and safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"38","author":"Ashina","year":"2018","journal-title":"Cephalalgia"},{"key":"2022011608400584000_92.5.466.6","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1177\/0333102419835459","article-title":"Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study","volume":"39","author":"Goadsby","year":"2019","journal-title":"Cephalalgia"},{"key":"2022011608400584000_92.5.466.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32534-0"},{"key":"2022011608400584000_92.5.466.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2012.02223.x"},{"key":"2022011608400584000_92.5.466.9","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"2022011608400584000_92.5.466.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02748.x"},{"key":"2022011608400584000_92.5.466.11","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/head.13162","article-title":"Psychometric evaluation of a novel instrument assessing the impact of migraine on physical functioning: the migraine physical function impact diary","volume":"57","author":"Kawata","year":"2017","journal-title":"Headache"},{"key":"2022011608400584000_92.5.466.12","first-page":"344","article-title":"Evaluating clinically meaningful within-subject change in functioning associated with migraine prevention using the migraine physical function impact diary (MPFID)","volume":"37","author":"Kawata","year":"2017","journal-title":"Cephalalgia"},{"key":"2022011608400584000_92.5.466.13","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026119331193"},{"key":"2022011608400584000_92.5.466.14","doi-asserted-by":"publisher","DOI":"10.1177\/0333102413497599"},{"key":"2022011608400584000_92.5.466.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2005.05.010"},{"key":"2022011608400584000_92.5.466.16","unstructured":"Bayliss M , Batenhorst A . The HIT-6TM A user\u2019s guide. QualityMetric Incorporated: Lincoln, RI, 2002."},{"key":"2022011608400584000_92.5.466.17","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-199304050-00006"},{"key":"2022011608400584000_92.5.466.18","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0b013e3181c1dc56"},{"key":"2022011608400584000_92.5.466.19","doi-asserted-by":"publisher","DOI":"10.1177\/0333102410381145"},{"key":"2022011608400584000_92.5.466.20","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/head.13383","article-title":"Measures of functioning in patients with episodic migraine: findings from a double-blind, randomized, placebo-controlled phase 2B trial with galcanezumab","volume":"58","author":"Ayer","year":"2018","journal-title":"Headache"},{"key":"2022011608400584000_92.5.466.21","doi-asserted-by":"publisher","DOI":"10.1177\/0333102418779543"},{"key":"2022011608400584000_92.5.466.22","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/WCO.0000000000000689","article-title":"How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? a patient's perspective","volume":"32","author":"Torres-Ferrus","year":"2019","journal-title":"Curr Opin Neurol"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2020-324396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T16:41:54Z","timestamp":1642351314000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2020-324396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":22,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,4,15]]},"published-print":{"date-parts":[[2021,5]]}},"alternative-id":["10.1136\/jnnp-2020-324396"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2020-324396","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]}}}